GNTA
Genenta Science S.p.A.
stockNASDAQADR
cancer immunotherapy - our gene therapy science to treat cancer we develop a gene transfer strategy into autologous hematopoietic stem/progenitor cells (hspcs) to target interferon-α expression to tumor-infiltrating monocytes/macrophages. an hiv-derived and genetically disabled viral vector - lentivirus - delivers the gene into the hspcs. interferon is a protein usually produced by the body in response to infections that also exhibits a powerful anti-tumor activity. however, the clinical use of interferon as a drug has been limited by its high toxicity. thanks to our innovative therapy, using a combination of transcriptional and microrna-mediated control, tumor-infiltrating monocytes/macrophages become capable to selectively express interferon limited to the tumor area, thus reducing its toxicity. based on these mechanisms, a population of tumor-infiltrating monocytes/macrophages, tie2-expressing monocytes (tems), are armed with a specific drug.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 0.82 | 2026-11-02 | +20.62% | 0.000 |
| 1M | 0.79 | 2026-10-09 | +25.45% | -3.890 |
| 3M | 1.30 | 2026-08-10 | -24.23% | -2.390 |
| 6M | 0.63 | 2026-05-08 | +57.32% | -2.063 |
| 1Y | 2.20 | 2025-11-10 | -55.23% | -1.018 |
| 2Y | 4.90 | 2024-11-08 | -79.90% | — |
| 5Y | 11.00 | 2021-12-15 | -91.05% | -0.117 |
Genenta Science S.p.A. (NASDAQ:GNTA) stock price today is $0.99, and today's volume is 337,503. The 30 day average volume is 115,134. GNTA market cap is $47.49M with 48.22M shares outstanding.